ACVRL1 and hereditary hemorrhagic telangiectasia: PAVMs develop in up to 50% of HHT patients, with a higher prevalence in HHT type 1 (associated with ENG mutations) compared to HHT type 2 (ACVRL1 mutations)1,4.